Gastric adenocarcinoma Trials in Guangzhou, China
Conditions / Gastric adenocarcinoma / Guangzhou, China
Gastric adenocarcinoma has been the subject of sustained clinical investigation across multiple research sites.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | COMPLETED | PHASE3 |
| NCT04850729 | Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | RECRUITING | — |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | UNKNOWN | PHASE1/PHASE2 |
| NCT04675983 | A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) | TERMINATED | PHASE3 |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT01567618 | Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer | COMPLETED | PHASE2 |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | COMPLETED | PHASE1 |
| NCT05365581 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | RECRUITING | — |
| NCT05235906 | A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer | UNKNOWN | PHASE2 |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | NOT_YET_RECRUITING | PHASE1/PHASE2 |